- Investing Ideas
- Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential
Swiss Pharmaceuticals & Biotech Large Cap High Growth Potential
Results
4
Large Cap Companies that analysts expect to have high earnings, revenue or cash flow growth in the next 3 years.
4 companies
Galderma Group
Market Cap: CHF 35.4b
Operates as a dermatology company worldwide.
GALD
CHF 146.90
7D
-5.2%
1Y
61.8%
Novartis
Market Cap: CHF 231.3b
Researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
NOVN
CHF 120.84
7D
-3.2%
1Y
24.7%
Sandoz Group
Market Cap: CHF 26.7b
Develops, manufactures, and markets generic and biosimilars worldwide.
SDZ
CHF 61.62
7D
-4.7%
1Y
67.9%
Lonza Group
Market Cap: CHF 34.4b
Supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally.
LONN
CHF 484.50
7D
-5.8%
1Y
-10.4%